6.20
-0.16%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Curanex Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Curanex Pharmaceuticals is based in Jericho, New York and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker CURX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $4.2m. At that date it held total assets of $11.6m and shareholders' equity of $11.2m.
If approved, Phyto-N could provide patients with new treatment options for various inflammatory conditions.
February 2026, Curanex successfully completed a pilot-scale batch of Phyto-N manufactured under Good Manufacturing Practice (GMP) standards.
2031 and reach more than $16 billion by the end of 2031 (Source: Transparency Market Research, 2023).
COVID-19 pandemic has created a massive global demand for effective preventive and therapeutic options against SARS-CoV-2 infection.
Phyto-N’s prospects and are committed to its careful and thorough evaluation as a potential new option in diabetes care.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Aug 2025
- Website
- curanexpharma.com ↗
- Head office
- 2 JERICHO PLAZA,, JERICHO, NY, 11753
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Jun LiuPresident, Chief Executive Officer, Director, since 2024
- Ms. Haiyan YangChief Financial Officer, Treasurer
- Dr. Liqin XieChief Operating Officer
- Mr. Ning ZhangChief Technology Officer
- Ms. Huijuan ZhongChief Science Officer
- Ms. Dian Ying JingSecretary, Director
- Mr. Yanming DuIndependent Director
- Mr. Xiaohui HaoIndependent Director
- Mr. Yong YanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is headquartered in Jericho, New York.
- Operates in the Pharmaceuticals industry with a focus on botanical drugs.
- Lead candidate Phyto-N targets multiple inflammatory diseases with a multi-target mechanism.
Weaknesses
- Company is in the developmental stage with no commercialized products yet.
- IPO is scheduled for 2025-08-26, indicating future capital raising needs.
- Drug development pipelines include six therapeutic areas but lack current commercial products.
Opportunities
- Phyto-N is being developed as an orally administered alternative for ulcerative colitis patients.
- Botanical drugs like Veregen and Fulyzaq/Mytesi offer potential market opportunities.
- Pipeline includes therapeutic areas such as autoimmune diseases and viral infections.
Threats
- Company is in developmental stage, which may lead to funding challenges.
- IPO date is in the future, creating uncertainty around market entry.
- No current commercial products to generate revenue until pipeline advances.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.